Dow Down1.19% Nasdaq Up0.14%

Poniard Pharmaceuticals, Inc. (PARD)

-Other OTC
2.14 Down 0.36(14.40%) Dec 30 - Nasdaq Real Time Price
Analyst OpinionGet Analyst Opinion for:
Recommendation Summary*
Mean Recommendation (this week):3.0
Mean Recommendation (last week):3.0

* (Strong Buy) 1.0 - 5.0 (Sell)

Price Target Summary
Mean Target:1.00
Median Target:1.00
High Target:1.00
Low Target:1.00
No. of Brokers:1

Data provided by Thomson/First Call

Upgrades & Downgrades History
DateResearch FirmActionFromTo
Jun 8, 2010Rodman & RenshawUpgradeMkt PerformMkt Outperform
Nov 18, 2009Canaccord AdamsDowngradeBuyHold
Nov 17, 2009Wedbush MorganDowngradeOutperformUnderperform
Nov 17, 2009Rodman & RenshawDowngradeMkt OutperformMkt Perform
Nov 16, 2009MerrimanDowngradeBuyNeutral
Oct 6, 2009BMO Capital MarketsInitiated Outperform
Jul 2, 2009Brean MurrayInitiated Buy
Mar 20, 2009Wedbush MorganInitiated Buy
Mar 18, 2009NeedhamInitiated Buy
Oct 3, 2007Credit SuisseInitiated Outperform

More Upgrades & Downgrades for PARD

Data provided by - Take a free trial
Complete Live market analysis of the U.S. stock and bond markets, technology stocks, economic releases, earnings reports, and day trading highlights.

Recommendation Trends
Current MonthLast MonthTwo Months AgoThree Months Ago
Strong Buy0000

Data provided by Thomson/First Call

Currency in USD.